Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Reirradiation of head and neck cancer in the era of intensity-modulated radiotherapy: patient selection, practical aspects, and current evidence

  • Kim, Yeon Sil (Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • Received : 2017.03.14
  • Accepted : 2017.03.28
  • Published : 2017.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Locoregional failure is the most frequent pattern of failure in locally advanced head and neck cancer patients and it leads to death in most of the patients. Second primary tumors occurring in the other head and neck region reach up to almost 40% of long-term survivors. Recommended and preferred retreatment option in operable patients is salvage surgical resection, reporting a 5-year overall survival of up to 40%. However, because of tumor location, extent, and underlying comorbidities, salvage surgery is often limited and compromised by incomplete resection. Reirradiation with or without combined chemotherapy is an appropriate option for unresectable recurrence. Reirradiation is carefully considered with a case-by-case basis. Reirradiation protocol enrollment is highly encouraged prior to committing patient to an aggressive therapy. Radiation doses greater than 60 Gy are usually recommended for successful salvage. Despite recent technical improvement in intensity-modulated radiotherapy (IMRT), the use of concurrent chemotherapy, and the emergence of molecularly targeted agents, careful patient selection remain as the most paramount factor in reirradiation. Tumors that recur or persist despite aggressive prior chemoradiation therapy imply the presence of chemoradio-resistant clonogens. Treatment protocols that combine novel targeted radiosensitizing agents with conformal high precision radiation are required to overcome the resistance while minimizing toxicity. Recent large number of data showed that IMRT may provide better locoregional control with acceptable acute or chronic morbidities. However, additional prospective studies are required before a definitive conclusion can be drawn on safety and effectiveness of IMRT.

Keywords

References

  1. Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2012;84:1198-205. https://doi.org/10.1016/j.ijrobp.2012.05.008
  2. Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004;15:1179-86. https://doi.org/10.1093/annonc/mdh308
  3. Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989;17:449-56. https://doi.org/10.1016/0360-3016(89)90094-1
  4. Bachar GY, Goh C, Goldstein DP, O'Sullivan B, Irish JC. Longterm outcome analysis after surgical salvage for recurrent tonsil carcinoma following radical radiotherapy. Eur Arch Otorhinolaryngol 2010;267:295-301. https://doi.org/10.1007/s00405-009-1070-0
  5. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27. https://doi.org/10.1056/NEJMoa0802656
  6. Weichselbaum RR, Beckett MA, Schwartz JL, Dritschilo A. Radioresistant tumor cells are present in head and neck carcinomas that recur after radiotherapy. Int J Radiat Oncol Biol Phys 1988;15:575-9. https://doi.org/10.1016/0360-3016(88)90297-0
  7. Stevens KR Jr, Britsch A, Moss WT. High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys 1994;29:687-98. https://doi.org/10.1016/0360-3016(94)90555-X
  8. Zbaren P, Nuyens M, Curschmann J, Stauffer E. Histologic characteristics and tumor spread of recurrent glottic carcinoma: analysis on whole-organ sections and comparison with tumor spread of primary glottic carcinomas. Head Neck 2007;29:26-32. https://doi.org/10.1002/hed.20502
  9. McDonald MW, Moore MG, Johnstone PA. Risk of carotid blowout after reirradiation of the head and neck: a systematic review. Int J Radiat Oncol Biol Phys 2012;82:1083-9. https://doi.org/10.1016/j.ijrobp.2010.08.029
  10. Ang KK, Jiang GL, Feng Y, Stephens LC, Tucker SL, Price RE. Extent and kinetics of recovery of occult spinal cord injury. Int J Radiat Oncol Biol Phys 2001;50:1013-20. https://doi.org/10.1016/S0360-3016(01)01599-1
  11. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S42-9. https://doi.org/10.1016/j.ijrobp.2009.04.095
  12. Nieder C, Grosu AL, Andratschke NH, Molls M. Update of human spinal cord reirradiation tolerance based on additional data from 38 patients. Int J Radiat Oncol Biol Phys 2006;66:1446-9. https://doi.org/10.1016/j.ijrobp.2006.07.1383
  13. Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000;110(3 Pt 2 Suppl 93):1-18.
  14. Kim AJ, Suh JD, Sercarz JA, et al. Salvage surgery with free flap reconstruction: factors affecting outcome after treatment of recurrent head and neck squamous carcinoma. Laryngoscope 2007;117:1019-23. https://doi.org/10.1097/MLG.0b013e3180536705
  15. Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008;26:5518-23. https://doi.org/10.1200/JCO.2007.15.0102
  16. Strojan P, Corry J, Eisbruch A, et al. Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate. Head Neck 2015;37:134-50. https://doi.org/10.1002/hed.23542
  17. Suh JD, Kim BP, Abemayor E, et al. Reirradiation after salvage surgery and microvascular free flap reconstruction for recurrent head and neck carcinoma. Otolaryngol Head Neck Surg 2008;139:781-6. https://doi.org/10.1016/j.otohns.2008.09.002
  18. Tortochaux J, Tao Y, Tournay E, et al. Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent. Radiother Oncol 2011;100:70-5. https://doi.org/10.1016/j.radonc.2011.06.025
  19. Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 2008;30:281-8. https://doi.org/10.1002/hed.20697
  20. Langer CJ, Harris J, Horwitz EM, et al. Phase II study of lowdose paclitaxel and cisplatin in combination with splitcourse concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol 2007;25:4800-5. https://doi.org/10.1200/JCO.2006.07.9194
  21. Argiris A, Li Y, Forastiere A. Prognostic factors and longterm survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004;101:2222-9. https://doi.org/10.1002/cncr.20640
  22. Lee N, Chan K, Bekelman JE, et al. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007;68:731-40. https://doi.org/10.1016/j.ijrobp.2006.12.055
  23. Kharofa J, Choong N, Wang D, et al. Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck. Int J Radiat Oncol Biol Phys 2012;83:690-5. https://doi.org/10.1016/j.ijrobp.2011.06.2010
  24. Siddiqui F, Patel M, Khan M, et al. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys 2009;74:1047-53. https://doi.org/10.1016/j.ijrobp.2008.09.022
  25. Heron DE, Ferris RL, Karamouzis M, et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys 2009;75:1493-500. https://doi.org/10.1016/j.ijrobp.2008.12.075
  26. Rwigema JC, Heron DE, Ferris RL, et al. Fractionated stereotactic body radiation therapy in the treatment of previously-irradiated recurrent head and neck carcinoma: updated report of the University of Pittsburgh experience. Am J Clin Oncol 2010;33:286-93.
  27. Cengiz M, Ozyigit G, Yazici G, et al. Salvage reirradiaton with stereotactic body radiotherapy for locally recurrent head-andneck tumors. Int J Radiat Oncol Biol Phys 2011;81:104-9. https://doi.org/10.1016/j.ijrobp.2010.04.027
  28. Heron DE, Rwigema JC, Gibson MK, Burton SA, Quinn AE, Ferris RL. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study. Am J Clin Oncol 2011;34:165-72.
  29. Lin R, Slater JD, Yonemoto LT, et al. Nasopharyngeal carcinoma: repeat treatment with conformal proton therapy: dose-volume histogram analysis. Radiology 1999;213:489-94. https://doi.org/10.1148/radiology.213.2.r99nv29489
  30. Takiar V, Garden AS, Ma D, et al. Reirradiation of head and neck cancers with intensity modulated radiation therapy: outcomes and analyses. Int J Radiat Oncol Biol Phys 2016;95:1117-31. https://doi.org/10.1016/j.ijrobp.2016.03.015
  31. Kuhn E, Molnar Z, Bohm K. Postirradiation changes on the lymphatics studied by lymphography. Rofo 1979;131:92-6. https://doi.org/10.1055/s-0029-1231383
  32. Hoebers F, Heemsbergen W, Moor S, et al. Reirradiation for head-and-neck cancer: delicate balance between effectiveness and toxicity. Int J Radiat Oncol Biol Phys 2011;81:e111-8. https://doi.org/10.1016/j.ijrobp.2011.01.004
  33. Sulman EP, Schwartz DL, Le TT, et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys 2009;73:399-409. https://doi.org/10.1016/j.ijrobp.2008.04.021
  34. Yu KH, Leung SF, Tung SY, et al. Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Head Neck 2005;27:397-405. https://doi.org/10.1002/hed.20161
  35. Patel PR, Salama JK. Reirradiation for recurrent head and neck cancer. Expert Rev Anticancer Ther 2012;12:1177-89. https://doi.org/10.1586/era.12.97
  36. Duprez F, Madani I, Bonte K, et al. Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory. Radiother Oncol 2009;93:563-9. https://doi.org/10.1016/j.radonc.2009.10.012
  37. Langendijk JA, Kasperts N, Leemans CR, Doornaert P, Slotman BJ. A phase II study of primary reirradiation in squamous cell carcinoma of head and neck. Radiother Oncol 2006;78:306-12. https://doi.org/10.1016/j.radonc.2006.02.003
  38. De Crevoisier R, Bourhis J, Domenge C, et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 1998;16:3556-62. https://doi.org/10.1200/JCO.1998.16.11.3556
  39. Yamazaki H, Kodani N, Ogita M, Sato K, Himei K. Reirradiation of head and neck cancer focusing on hypofractionated stereotactic body radiation therapy. Radiat Oncol 2011;6:98. https://doi.org/10.1186/1748-717X-6-98
  40. Ohizumi Y, Tamai Y, Imamiya S, Akiba T. Prognostic factors of reirradiation for recurrent head and neck cancer. Am J Clin Oncol 2002;25:408-13. https://doi.org/10.1097/00000421-200208000-00018
  41. Mendenhall WM, Mendenhall CM, Malyapa RS, Palta JR, Mendenhall NP. Re-irradiation of head and neck carcinoma. Am J Clin Oncol 2008;31:393-8. https://doi.org/10.1097/COC.0b013e3181637398
  42. Popovtzer A, Gluck I, Chepeha DB, et al. The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets. Int J Radiat Oncol Biol Phys 2009;74:1342-7. https://doi.org/10.1016/j.ijrobp.2008.10.042
  43. Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2006;64:382-91. https://doi.org/10.1016/j.ijrobp.2005.07.005
  44. Choe KS, Haraf DJ, Solanki A, et al. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer 2011;117:4671-8. https://doi.org/10.1002/cncr.26084
  45. Nagar YS, Singh S, Datta NR. Chemo-reirradiation in persistent/recurrent head and neck cancers. Jpn J Clin Oncol 2004;34:61-8. https://doi.org/10.1093/jjco/hyh017
  46. Vargo JA, Heron DE, Ferris RL, et al. Prospective evaluation of patient-reported quality-of-life outcomes following SBRT ${\pm}$ cetuximab for locally-recurrent, previously-irradiated head and neck cancer. Radiother Oncol 2012;104:91-5. https://doi.org/10.1016/j.radonc.2012.04.020
  47. McDonald MW, Lawson J, Garg MK, et al. ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys 2011;80:1292-8. https://doi.org/10.1016/j.ijrobp.2011.02.014

Cited by

  1. Association of Fludeoxyglucose F 18-Labeled Positron Emission Tomography and Computed Tomography With the Detection of Oropharyngeal Cancer Recurrence vol.144, pp.11, 2017, https://doi.org/10.1001/jamaoto.2018.2143
  2. Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT vol.13, pp.1, 2017, https://doi.org/10.1186/s13014-018-1080-4
  3. Survival benefit of re-irradiation in esophageal Cancer patients with Locoregional recurrence: a propensity score-matched analysis vol.13, pp.1, 2017, https://doi.org/10.1186/s13014-018-1122-y
  4. Assessment of the modulation degrees of intensity-modulated radiation therapy plans vol.13, pp.1, 2018, https://doi.org/10.1186/s13014-018-1193-9
  5. Reirradiation for Recurrent Nasopharyngeal Carcinomas: Experience From an Academic Tertiary Center in a Low- to Middle-Income Country vol.5, pp.None, 2017, https://doi.org/10.1200/jgo.18.00191
  6. The DAHANCA 32 study: Electrochemotherapy for recurrent mucosal head and neck cancer vol.41, pp.2, 2019, https://doi.org/10.1002/hed.25454
  7. A 3D-printed patient-specific applicator guide for use in high-dose-rate interstitial brachytherapy for tongue cancer: a phantom study vol.64, pp.13, 2017, https://doi.org/10.1088/1361-6560/ab277e
  8. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics vol.25, pp.14, 2017, https://doi.org/10.1158/1078-0432.ccr-18-0871
  9. eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after definitive surgery and adjuvant radiotherapy vol.14, pp.11, 2019, https://doi.org/10.1371/journal.pone.0225537
  10. A prospective evaluation of health‐related quality of life after skull base re‐irradiation vol.42, pp.3, 2017, https://doi.org/10.1002/hed.26037
  11. Selection of systemic therapy in patients with locally advanced and recurrent/metastatic head and neck cancer: RAND-based expert opinion by an Italian multidisciplinary panel vol.106, pp.3, 2020, https://doi.org/10.1177/0300891619868289
  12. A Novel Salvage Option for Local Failure in Prostate Cancer, Reirradiation Using External Beam or Stereotactic Radiation Therapy: Systematic Review and Meta-Analysis vol.5, pp.5, 2017, https://doi.org/10.1016/j.adro.2020.04.022
  13. Radiation necrosis of the pharyngeal soft tissue: Unique clinical entity reconstructed with a previously unreported composite brachioradialis and flexor digitorum superficialis radial forearm flap vol.42, pp.10, 2017, https://doi.org/10.1002/hed.26405
  14. Intensity-Modulated Radiotherapy-Based Reirradiation for Head and Neck Cancer: A Multi-institutional Study by Korean Radiation Oncology Group (KROG 1707) vol.52, pp.4, 2020, https://doi.org/10.4143/crt.2020.310
  15. The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer vol.15, pp.1, 2017, https://doi.org/10.1186/s13014-020-01531-5
  16. Multi-Institutional Study Validates Safety of Intraoperative Cesium-131 Brachytherapy for Treatment of Recurrent Head and Neck Cancer vol.11, pp.None, 2017, https://doi.org/10.3389/fonc.2021.786216
  17. Long-term outcomes and safety after reirradiation in locally recurrent nasopharyngeal carcinoma in a non-endemic area vol.197, pp.3, 2017, https://doi.org/10.1007/s00066-020-01647-3
  18. Automated Non-Coplanar VMAT for Dose Escalation in Recurrent Head and Neck Cancer Patients vol.13, pp.8, 2017, https://doi.org/10.3390/cancers13081910
  19. Re-irradiation for recurrent or second primary head and neck cancer vol.39, pp.4, 2017, https://doi.org/10.3857/roj.2021.00640